Skip to main content
Top
Published in: Reactions Weekly 1/2024

01-05-2024 | Alemtuzumab | Case report

Alemtuzumab/Methylprednisolone

Thyroid eye disease and lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Muller I, et al. Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab. European Thyroid Journal 13: No. 2, Apr 2024. Available from: URL: https://dx.doi.org/10.1530/ETJ-23-0236 Muller I, et al. Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab. European Thyroid Journal 13: No. 2, Apr 2024. Available from: URL: https://​dx.​doi.​org/​10.​1530/​ETJ-23-0236
Metadata
Title
Alemtuzumab/Methylprednisolone
Thyroid eye disease and lack of efficacy
Publication date
01-05-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57922-y

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue